ADK | Adenosine kinase | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
ANXA1 | Annexin A1 | Cancer-related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Transporters
| | | | | Expressed in all |
APEX1 | APEX nuclease (multifunctional DNA repair enzyme) 1 | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
BLVRB | Biliverdin reductase B (flavin reductase (NADPH)) | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Expressed in all |
CCND1 | Cyclin D1 | Cancer-related genes Disease related genes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
CD33 | CD33 molecule | CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Mixed |
CD4 | CD4 molecule | CD markers FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
CD44 | CD44 molecule (Indian blood group) | Blood group antigen proteins Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
CKB | Creatine kinase, brain | Cancer-related genes Candidate cardiovascular disease genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
CPT1A | Carnitine palmitoyltransferase 1A (liver) | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
CPT2 | Carnitine palmitoyltransferase 2 | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
DNMT1 | DNA (cytosine-5-)-methyltransferase 1 | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Transcription factors
| | | | | Expressed in all |
EGFR | Epidermal growth factor receptor | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
ERBB2 | V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
FASN | Fatty acid synthase | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
FGF2 | Fibroblast growth factor 2 (basic) | Cancer-related genes Candidate cardiovascular disease genes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Mixed |
GANAB | Glucosidase, alpha; neutral AB | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Expressed in all |
GSR | Glutathione reductase | Cancer-related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
GSS | Glutathione synthetase | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
HDAC1 | Histone deacetylase 1 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
HDAC2 | Histone deacetylase 2 | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
HMMR | Hyaluronan-mediated motility receptor (RHAMM) | CD markers FDA approved drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
HPRT1 | Hypoxanthine phosphoribosyltransferase 1 | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
ITGB1 | Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) | Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
JUN | Jun proto-oncogene | Cancer-related genes FDA approved drug targets Predicted intracellular proteins Transcription factors
| | | | | Expressed in all |
MAOA | Monoamine oxidase A | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted membrane proteins
| | | | | Mixed |
MAP2 | Microtubule-associated protein 2 | FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
MAP2K2 | Mitogen-activated protein kinase kinase 2 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Expressed in all |
MET | MET proto-oncogene, receptor tyrosine kinase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Expressed in all |
NFKB1 | Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 | Cancer-related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins RAS pathway related proteins Transcription factors
| | | | | Expressed in all |
NR3C1 | Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) | Disease related genes FDA approved drug targets Nuclear receptors Plasma proteins Predicted intracellular proteins Transcription factors
| | | | | Expressed in all |
PDXK | Pyridoxal (pyridoxine, vitamin B6) kinase | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PLA2G4A | Phospholipase A2, group IVA (cytosolic, calcium-dependent) | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Mixed |
PLIN3 | Perilipin 3 | FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PRDX5 | Peroxiredoxin 5 | Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PRKAB1 | Protein kinase, AMP-activated, beta 1 non-catalytic subunit | FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
PSMB1 | Proteasome (prosome, macropain) subunit, beta type, 1 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PTGS1 | Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) | Cancer-related genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
RPL3 | Ribosomal protein L3 | FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins Ribosomal proteins
| | | | | Expressed in all |
RRM2B | Ribonucleotide reductase M2 B (TP53 inducible) | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
SIRT5 | Sirtuin 5 | FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
SOAT1 | Sterol O-acyltransferase 1 | Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
SRC | SRC proto-oncogene, non-receptor tyrosine kinase | Cancer-related genes Cytoskeleton related proteins Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Mixed |
SV2A | Synaptic vesicle glycoprotein 2A | FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
TBXAS1 | Thromboxane A synthase 1 (platelet) | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
TOP1 | Topoisomerase (DNA) I | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
TOP2A | Topoisomerase (DNA) II alpha 170kDa | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
TOP2B | Topoisomerase (DNA) II beta 180kDa | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |